An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment

Trial Profile

An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2014

At a glance

  • Drugs Kanglaite (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors KangLaiTe USA
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top